Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Barcelona
Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Madrid 29 Barcelona 29 Málaga 15 Seville 13 A Coruña 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Merck Sharp & Dohme LLC113 Novartis Pharmaceuticals111 Janssen Research & Development, LLC96 Hoffmann-La Roche85 Clear sponsor filter
Site location
Madrid29 Barcelona29 Málaga15 Seville13 A Coruña9
All 45 locations
Target enrolment
to

Trials with a site in Barcelona

29 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Daiichi Sankyo
Phase 3
103
Barcelona, Madrid
2026-09-30
Recruiting
Daiichi Sankyo
Phase 1/2
220
Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife
2026-09-17
Recruiting
Daiichi Sankyo
Phase 3
686
A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga
2025-10-24
Recruiting
Daiichi Sankyo
Phase 1
76
Barcelona, Madrid, Seville
2025-07-17
Recruiting
Daiichi Sankyo
Phase 3
582
A Coruña, Barcelona, Córdoba, El Palmar, Madrid, Palma, Pamplona, Planta Baja
2025-03-19
Recruiting
Daiichi Sankyo
Phase 3
726
Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia
2025-02-27
Active, closed
Daiichi Sankyo
Phase 2
335
A Coruña, Barcelona, Madrid, Málaga
2025-01-06
Active, closed
Daiichi Sankyo
Phase 3
700
Albacete, Alicante, Badalona, Barcelona, Burgos, Cáceres, Córdoba, Las Palmas
2024-11-19
Recruiting
Daiichi Sankyo
Phase 1/2
123
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo
2024-07-22
Recruiting
Daiichi Sankyo
Phase 3
540
Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga
2024-05-21
Recruiting
Daiichi Sankyo
Phase 1/2
680
Barcelona, Madrid, Seville
2024-04-10
Recruiting
Daiichi Sankyo
Phase 2/3
860
Barcelona, Jaén, Madrid, Pamplona, Valencia
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Barcelona, Madrid, Málaga, Seville, Valencia
2024-02-26
Recruiting
Daiichi Sankyo
Phase 3
50
A Coruña, Barcelona, Distrito de Les Corts, L'Hospitalet de Llobregat, Madrid
2024-01-05
Recruiting
Daiichi Sankyo
Phase 3
250
Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona
2023-12-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2023-08-18
Recruiting
Daiichi Sankyo
Phase 1
128
Barcelona
2023-05-30
Active, closed
Daiichi Sankyo
Phase 3
1,170
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza
2023-01-11
Active, closed
Daiichi Sankyo
Phase 3
586
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville
2022-07-08
Active, closed
Daiichi Sankyo
Phase 2
187
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2022-03-09
Active, closed
Daiichi Sankyo
Phase 3
740
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2022-03-04
Active, closed
Daiichi Sankyo
Phase 2
155
Barcelona, Madrid, Seville
2021-06-03
Active, closed
Daiichi Sankyo
Phase 3
490
Barcelona, Madrid, Pamplona, Santiago de Compostela, Valencia
2021-05-21
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Seville, Badalona, Majadahonda, Barcelona, Madrid, Málaga, Zaragoza
2021-02-02
Active, closed
Daiichi Sankyo
Phase 3
605
Barcelona, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2020-12-21
Active, closed
Daiichi Sankyo
Phase 3
1,600
Bilbao, El Palmar, Reus, A Coruña, Alcorcón, Alicante, Badajoz, Barcelona
2020-12-04
Active, closed
Daiichi Sankyo
Phase 1
145
Barcelona, Madrid, Majadahonda
2020-09-15
Active, closed
Daiichi Sankyo
Phase 1
115
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Seville, Zaragoza
2020-02-10
Active, closed
Daiichi Sankyo
Phase 1
312
Barcelona, Madrid, Pamplona
2017-10-30
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Barcelona that also match the filters currently applied.

How many clinical trials are recruiting in Barcelona?

14 of the 29 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barcelona), 29 studies
PhaseStudiesRecruitingShare
Phase 314648.3%
Phase 15217.2%
Phase 25117.2%
Phase 1/24413.8%
Phase 2/3113.4%

Most active sponsors

Lead sponsors with the most studies (Barcelona)
Lead sponsorStudiesRecruiting
Daiichi Sankyo2914
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.